Mon, Jun 2, 10:02 AM (16 days ago)
**Agilent Technologies, Inc. (A) - Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $1.67 billion (up 6% YoY) - Products: $1.19 billion (up 5% YoY) - Services: $482 million (up 8% YoY) - **Net Income:** $215 million (down 30% YoY) - **Earnings per Share (EPS):** $0.75 (down 27% YoY) - **Cash Flow from Operations:** $652 million (down 18% YoY) - **Cash Position:** $1.49 billion (up 12% YoY) **Profit Margins:** - **Gross Margin:** 51.9% (down 2.5 points YoY) - **Operating Margin:** 18.0% (down 5.1 points YoY) **Segment Performance:** - **Life Sciences & Diagnostics:** $654 million (up 8% YoY) - **Agilent CrossLab:** $713 million (up 7% YoY) - **Applied Markets:** $301 million (down 1% YoY) **Trends & Uncertainties:** - **Tariffs & Trade Policies:** Potential adverse impact on costs and revenue. - **Market Demand:** Steady recovery expected in key end markets. - **Inflation & Costs:** Active mitigation strategies in place. **Future Operations Impact:** - **Investments:** Continued focus on R&D, manufacturing, and market expansion. - **Dividends & Buybacks:** $0.248 per share dividend declared; $119 million remaining for buybacks. **Risks:** - **Economic Conditions:** Sensitivity to global economic trends. - **Currency Fluctuations:** Exposure to foreign exchange rate changes. - **Regulatory Environment:** Compliance with evolving regulations. - **Supply Chain:** Dependence on contract manufacturing and outsourcing. **Outlook:** - **Revenue Growth:** Expected to mitigate tariff impacts by year-end. - **Margin Protection:** Strategies to sustain long-term growth despite pressures. - **Market Opportunities:** Optimistic about life sciences, diagnostics, and applied markets.